Acquisitions and mergers

Smith & Nephew, Inc. acquires Kalypto Medical, Inc., further investing in Negative Pressure Wound Therapy to deliver continual innovation

The First Medical Device Acquisition in China for the Johnson & Johnson Family of Companies is Guangzho Bioseal Who’s Biologic Product Complements J&J’s Existing Haemostat Portfolio.

We didn’t see this one coming. Royal DSM, which describes itself as a life sciences and material sciences company, sees a great strategic fit with regenerative medicine specialist Kensey Nash, which has encouraged the Dutch based outfit to stump up a number well ahead of the current share price.

Not many weeks go by without news of a Covidien acquisition, so its not too surprising when the tech titan takes a shine to a company who’s product can help place its hernia meshes in a speedy and effective fashion.

Orthofix’s foray into bracing and cold therapy is over with its announcement that it’s selling Breg, acquired in 2003.

CareFusion continues its “simplify and focus” strategy with divestment of its Nicolet business to Natus Medical for a reported $58M.

There was an inevitability about the whole thing, but still J&J and Synthes execs must be relieved that the EU commission into their mega deal has agreed to the takeover following J&J’s concessionary divestiture of its existing trauma business. Wonder how those guys are feeling though.

Foillowing its acquisition of General Biotechnology LLC, Cook Group has announced its formation of Cook General Biotechnology LLC, in a move which will help reinforce its position in the cellular therapy field.

What an interesting deal. J&J’s Ethicon, not known for its soft negotiating stance, has agreed a deal in which it pays Angiotech for IP relating to the company’s Quill suture technology, yet is allowing the pharma company to keep on selling it.

This week’s View From The Med is available for your perusal here. Like a cow chewing the cud, why not spend five minutes enjoying our sideways glance at the main events of the past week?

The medical devices giant that is Covidien, shows its still on the acquisition trail with the announcement that it is to spend $300M buying Israeli respiratory monitoring company Oridion.

Biomet has an exclusive, binding offer of $280M on the table for J&J’s DePuy Trauma division. The deal is thought to represent J&J’s concession, extracted from the leviathan by an EU commission, in order to ratify its $21Bn takeover of Synthes.

Consolidation of contract manufacturing of medical devices, as Sandvik Medical Solutions finds a new home following its acquisition by Orchid Orthopaedic Solutions.

AngioDynamics and Microsulis Medical are looking lovingly at each other as they enter into what we romantics call a “multi-faceted strategic relationship”. Possibly more.

Another Covidien Acquisition, this time in its Airway and Ventilation Business, with announced purchase of Newport Medical Inc.

According to sources “familiar with the matter”, Johnson and Johnson’s acquisition of Synthes, first announced last year, is now likely to gain approval from the European Commission following its investigation and concession from J&J.